Neurotensin is a 13-amino-acid peptide best known for what it does in the brain and gut, where it tunes pain, appetite, and dopamine signaling. A study published July 1 in Science Translational Medicine ↗ found it doing something no one had pinned on it before: acting as a brake on the damage that turns an injured heart into a failing one.
The peptide showed up in an unexpected place. After the heart was stressed by pressure overload (a surgical model called transverse aortic constriction) or a heart attack, the lymphatic vessels threaded through the heart muscle ramped up their production of neurotensin. In cultured mouse and human cells, that neurotensin told cardiomyocytes, the muscle cells that do the pumping, not to enlarge. It told fibroblasts, the cells that lay down scar tissue, to stand down. Both effects ran through a single receptor, NTSR2, and a familiar protective second messenger called cGMP.
The work came out of the Max Planck Institute for Heart and Lung Research in Bad Nauheim, Germany, led by Niharika Shiva and Haruya Kawase. The team tested the idea from both directions. When they deleted neurotensin from the lymphatic vessels of mice, the animals developed worse muscle thickening and scarring after injury. When they switched off the NTSR2 receptor in heart muscle or in scar-forming fibroblasts, the same thing happened. Then they ran it forward: a selective NTSR2 agonist called NT150 reproduced neurotensin's calming effect and improved both remodeling and heart function in mice, after pressure overload and after a heart attack.
Loss of function and gain of function pointing the same way is the strongest version of this kind of argument. Remove the pathway and the heart does worse. Add a molecule that pushes the pathway and it does better. Both are true in the same paper.
They also dripped NT150 onto freshly cut heart tissue from people with heart failure. It raised cGMP and quieted the signaling that drives muscle thickening. That is as close to a patient as this work gets. No one has been treated. NT150 is a research compound, not a drug, and everything load-bearing here happened in cells, in mice, and in a dish.
The selectivity is the interesting part for anyone thinking about turning this into a therapy. Neurotensin given whole-body hits receptors all over the brain and gut, which is exactly why it has never been an easy drug to build. Aiming at NTSR2 specifically, rather than the better-studied NTSR1, is an attempt to keep the heart benefit while leaving the peptide's other jobs alone. Whether a molecule can hold that line in a living person is the open question, and it is a hard one.
Neurotensin ↗ sits on peptidemodel mostly as a research tool, catalogued for its brain-and-gut signaling. A protective role in the heart, produced locally by the organ's own lymphatic plumbing, is a reminder that a peptide's known biology is often just the part someone looked at first.